Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA’s ODAC: The Advisory Committee That Can Only Say ‘No’

Nov 01 2022

• By Michael McCaughan

FDA stop sign. Sarah Silbiger/Getty Images — • Source: Sarah Silbiger/Getty Images

Related Content

Puma Breaks A Long Losing Streak For Sponsors At ODAC

Jun 04 2017

Mesoblast’s Cell Therapy For Pediatric GVHD Gets US Panel Green Light Despite FDA's "Substantial Concerns"

Aug 14 2020

GlaxoSmithKline Survives Technical Woes To Win US FDA Panel Nod For Belantamab

Jul 15 2020

Secura’s Copiktra: Trial Design, Shifting Standard Of Care Could Spell The End For Third-Line CLL/SLL

Sep 23 2022

ODAC Applauds Effort, But Votes Against Y-mAbs’ I-Omburtamab In Neuroblastoma

Oct 28 2022

Y-mAbs’ I-Omburtamab Offers Another Example Of The Limits To US FDA’s Regulatory Flexibility

Nov 01 2022

FDA Oncology Advisory Committee Is Still Pazdur’s Center of Excellence

Sep 20 2016

Related Companies

Y-mAbs Therapeutics Inc.

Mesoblast Limited

GSK plc

Additional Topics

United States Advisory Committees Drug Approval Standards Drug Review Regulation Cancer BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window